Kusurinomadoguchi (5592) Q1 2027 earnings summary

Executive summary

• Consolidated revenue for Q1 FY3/2027 rose 25.0% year-over-year to ¥3,643.9 million, driven by growth in Healthcare Automation and Core Systems, M&A, and regulatory-driven demand.

• Operating profit increased 24.6% year-over-year, reaching ¥784.1 million, with recurring gross profit and net income attributable to parent up 61.0%.

• Growth was fueled by increased online prescription acceptance, higher pharmaceutical distribution volumes, and more system users.

• Business segments were renamed to reflect expanded healthcare automation and wellness focus.

Financial highlights

• Q1 FY3/2027 revenue: ¥3,643.9 million (+25.0% YoY); operating profit: ¥784.1 million (+24.6% YoY); net income: ¥623.0 million (+61.0% YoY); EPS: ¥54.43.

• Gross profit margin improved, with gross profit at ¥2,099.1 million; recurring gross profit: ¥1,069 million (+26.4% YoY); EBITDA: ¥1,194 million (+22.0% YoY).

• Gross margin and EBITDA margin remained strong, supported by recurring revenue growth and strategic M&A.

• Total assets increased 53.5% year-over-year to ¥18,227.9 million, with cash and equivalents up 138.8% to ¥4,509 million.

• Comprehensive income increased to ¥605.8 million from ¥411.6 million year-over-year.

Outlook and guidance

• FY3/2027 full-year revenue forecast: ¥14,400 million (+16.8% YoY); operating profit forecast: ¥3,100 million (+15.6% YoY); net income forecast: ¥3,100 million (+5.0% YoY).

• Q1 progress rates for revenue and profit are at 25% of full-year targets, indicating solid progress.

• No changes to previously announced earnings or dividend forecasts.

• Medium-term plan targets ¥20,000 million recurring revenue and ¥5,000 million operating profit by FY3/2030.